Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2017

Open Access 01-06-2017 | Erratum

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Authors: S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, J. M. Stewart

Published in: Investigational New Drugs | Issue 3/2017

Login to get access

Excerpt

Erratum to: Invest New Drugs …
Metadata
Title
Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors
Authors
S. Fu
H. Hirte
S. Welch
T. T. Ilenchuk
T. Lutes
C. Rice
N. Fields
A. Nemet
D. Dugourd
S. Piha-Paul
V. Subbiah
L. Liu
J. Gong
D. Hong
J. M. Stewart
Publication date
01-06-2017
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0455-y

Other articles of this Issue 3/2017

Investigational New Drugs 3/2017 Go to the issue

PHASE II STUDIES

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

PHASE I STUDIES

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors

SHORT REPORT

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience

PRECLINICAL STUDIES

A truncated apoptin protein variant selectively kills cancer cells

PRECLINICAL STUDIES

State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261

PRECLINICAL STUDIES

Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits